Droxinostatは一種の選択性HDAC阻害剤で、HDACs 6と8に最も有効に作用して、IC50値が2.47μMと1.46 μMに分かれて、、HDACs 6と8に作用する選択性がHDAC3に作用する選択性より8倍高くなって、HDAC1、2、4、5、7、9と10に抑制作用を表しません。

価格 在庫  
USD 88 あり
USD 88 あり
USD 151 あり
USD 340 あり

Droxinostat 化学構造
分子量: 243.69





  • Compare HDAC Inhibitors
  • 研究分野
  • Combination Therapy



製品説明 Droxinostatは一種の選択性HDAC阻害剤で、HDACs 6と8に最も有効に作用して、IC50値が2.47μMと1.46 μMに分かれて、、HDACs 6と8に作用する選択性がHDAC3に作用する選択性より8倍高くなって、HDAC1、2、4、5、7、9と10に抑制作用を表しません。
IC50 16.9 μM 2.47 μM 1.46 μM [3]
In vitro試験 Droxinostat is originally identified as a sensitizer of PPC-1 cells to FAS and TRAIL by downregulating the expression of c-Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein (c-FLIP). [1] In PPC-1 cells cultured in suspension but not adherent conditions, Droxinostat (20 μM–60 μM) sensitizes cells to anoikis by initially activating caspase 8 with subsequent activation of the mitochondrial pathway. Similarly, Droxinostat also sensitizes other cancer cell lines including PC-3, DU-145, T47D, and OVCAR-3, but not LNCaP or MB-MDA-468, to anoikis or CH-11-induced apoptosis. [2] However, the direct targets of Droxinostat remains enigma until recently. It is revealed that in histone deacetylases (HDAC) isoform 1-10, Droxinostat selective inhibits HDAC3, 6, and 8, with IC50 values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively, without inhibiting other HDAC members (IC50 > 20 μM). [3] In MCF-7 breast cancer cells, Droxinostat (10 μM–100 μM) sensitizes cells to apoptosis by decreasing c-FLIPL and c-FLIPS expression, reducing cell survival, and inducing apoptosis. [4]
In vivo試験 In SCID mice models, Droxinostat (30 μM)-treated PPC-1 cells results in decreased distant tumor formation than untreated cells. [2]
特集 Selective inhibitor of HDAC3, HDAC6,and HDAC8.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

HDAC Inhibition Assay HDAC inhibition is assessed using the CycLex HDACs fluorometric assay according to the manufacturer's protocol and using crude nuclear extract from HeLa cells (principally HDAC1 and HDAC2). The relative activity is expressed as (fluorescence intensity of treated samples/fluorescence intensity of controls) × 100

細胞アッセイ: [1]

細胞株 PPC-1 cells
濃度 0–100 μM, dissolved in DMSO (final concentration of DMSO is 0.5%)
反応時間 24 hours
実験の流れ PPC-1 cells (1 × 104) are seeded overnight into 96-well flat-bottomed plates in 100 μL of medium containing 2.5% FCS. The next day, Droxinostat is added. CH-11 antibody (100 ng/mL) is then added and the cells are incubated for 24 hours before assessing cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye reduction assay.

動物実験: [2]

動物モデル Male severe combined immunodeficient (SCID) mice models treated with PPC-1 cells
製剤 dsRed-PPC-1 cells that treated with Droxinostat (30 μM) or PBS buffer control are either injected via the tail vein or subcutaneously into the hind limbs

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Droxinostat SDF
分子量 243.69


CAS No. 99873-43-5
保管 3年-20℃
2年-80℃in solvent
別名 NS 41080
溶解度 (25°C) * In vitro DMSO 49 mg/mL (201.07 mM)
Ethanol 49 mg/mL (201.07 mM)
Water <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide

文献中の引用 (5)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related HDAC 阻害剤

  • LMK-235

    LMK-235は一種のHDAC4とHDAC5選択性阻害剤で、IC50値が11.9 nM と 4.2 nMに分かれます。

  • CAY10603

    CAY10603は一種の有効的で、選択性的なHDAC6阻害剤で、IC50値が2 pMになって、HDAC6に作用する選択性はHDACsに作用する選択性より200倍以上が高くなります。

  • 4SC-202

    4SC-202は一種の選択性I型HDAC阻害剤で、HDAC1、HDAC2とHDAC3に作用する時のIC50値が1.20 μM、1.12 μMと0.57 μMそれぞれに分かれて、Lysine specific demethylase 1 (LSD1)にも抑制活性を表します。臨床1期。

  • HPOB

    HPOBは一種の有効的で、選択性HDAC6阻害剤で、IC50値が56 nMになって、HDAC6に作用する選択性は他のHDACsに作用する選択性より30倍以上が高くなります。

  • Panobinostat (LBH589)

    Panobinostat (LBH589) は一種の新たで、広範なHDAC阻害剤で、無細胞試験でIC50値が5 nMです。臨床3期。

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA)は一種のHDAC阻害剤で、無細胞試験でIC50値が約10 nMです。

  • Entinostat (MS-275)

    Entinostat (MS-275)はHDAC1とHDAC3を強く抑制して、無細胞試験でIC50値が0.51μMと1.7μMに分かれて、抑制作用がHDACs 4/6/8/10より良くなリます。臨床3期。

  • Trichostatin A (TSA)

    Trichostatin A (TSA)は一種のHDAC阻害剤で、無細胞試験でIC50値が1.8 nM程度です。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)は一種の有効なHDAC1とHDAC2阻害剤で、無細胞試験でIC50値が36 nMと47 nMに分かれます。

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966



Tags: Droxinostatを買う | Droxinostat供給者 | Droxinostatを購入する | Droxinostat費用 | Droxinostat生産者 | オーダーDroxinostat | Droxinostat代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID